Fluticasone
Brand names: Flixotide, Flixonase, Flutiform, Cutivate
Fluticasone is an inhaled (or intranasal) corticosteroid used as preventer therapy in asthma and to control allergic rhinitis and nasal polyps.
ClinCalc Pro is rebuilding its dose data from primary open sources — the manufacturer SmPC (eMC), the WHO Model Formulary and other official references — under clinician review. This drug's structured dose is not yet published here. Confirm all doses against the product SmPC and your local formulary before prescribing.
Clinical monograph
How it works
It is a potent glucocorticoid that binds the glucocorticoid receptor to suppress airway inflammation, reducing inflammatory cell activity, mucosal oedema and bronchial hyper-responsiveness.
Prescribing in practice
- It is a preventer for regular use and does not relieve acute bronchospasm, so patients must retain a separate reliever inhaler.
- Rinse the mouth after inhaled use to reduce the risk of oral candidiasis and dysphonia.
- Prolonged or high-dose use carries a risk of systemic corticosteroid effects, including adrenal suppression and reduced growth velocity in children.
Monitoring
Monitor asthma control and inhaler technique, and monitor growth in children on long-term inhaled corticosteroids.
Counselling the patient
- Use it every day as prescribed even when you feel well, as it works by preventing flare-ups.
- Rinse your mouth and spit out after each dose.
- Carry your separate reliever inhaler for sudden breathlessness.
Evidence & guidelines
Inhaled corticosteroids are the cornerstone of asthma preventer therapy in NICE and national guidance, reducing exacerbations and symptoms.
Reference: BTS/SIGN; NICE NG80/NG115; Drug verified in RxNorm (NLM); confirm dosing against the manufacturer SPC (eMC). Verify against your local formulary and current prescribing references before prescribing. Monograph status: clinician-reviewed (2026-07-04).
Related
Curated clinical cross-links plus same-class fallbacks.
- Acute Asthma in Adults · BTS/SIGN British Guideline on Asthma 2019; NICE NG80
- Pulmonary Embolism Assessment · NICE NG158; ESC 2019 PE Guidelines
- Acute Exacerbation of COPD (AECOPD) · NICE NG115; GOLD 2024
- Spontaneous Pneumothorax (Adult) · BTS Pleural Disease 2023
- Atypical Pneumonia (Legionella / Mycoplasma / Chlamydophila) · BTS 2023; IDSA
- COPD Exacerbation Management · NICE NG115 / GOLD 2024